https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32516 Wed 13 Jun 2018 11:02:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42132 Thu 25 Aug 2022 16:25:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38735 Thu 20 Jan 2022 14:53:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49451 null (NSG) mice to incorporate two levels of humanization; the primary tumor and TME, and the secondary metastatic bone organ. Bioluminescent imaging, histology, and immunohistochemistry were used to study metastasis of human PC-3 and LNCaP PCa cells from the prostate to tissue-engineered bone. Here we show pre-seeding scaffolds with human osteoblasts increases the human cellular and extracellular matrix content of bone constructs, compared to unseeded scaffolds. The humanized prostate TME showed a trend to decrease metastasis of PC-3 PCa cells to the tissue-engineered bone, but did not affect the metastatic potential of PCa cells to the endogenous murine bones or organs. On the other hand, the humanized TME enhanced LNCaP tumor growth and metastasis to humanized and murine bone. Together this demonstrates the importance of the TME in PCa bone tropism, although further investigations are needed to delineate specific roles of the TME components in this context.]]> Thu 18 May 2023 09:45:06 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42724 Thu 01 Sep 2022 13:18:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24042 Sat 24 Mar 2018 07:11:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33247 7 cutpoint identified in 2014 for the BP and STI endpoints. A tertiary objective of the trial is to determine whether intercurrent medical conditions will impact independently on delayed radiotherapy morbidity and other treatment related morbidity.]]> Mon 23 Sep 2019 13:37:53 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44147 Mon 10 Oct 2022 09:17:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25794 per se have the potential to mediate anti-cancer effects, act synergistically with currently used chemotherapeutics and/or radiotherapy regimens and reduce their side effects. Recently, scientists became conscious that TE&RM strategies may not only be utilized to advance contemporary tissue reconstruction techniques but also to develop personalized diagnostic tools and clinically relevant disease models for cancer patients. Eventually, prospective randomized clinical trials combined with comparative outcome analyses are a conditio sine qua non to shape the benefits of personalized regenerative therapies for the standardized management of patients with musculoskeletal tumours.]]> Fri 01 Apr 2022 09:28:03 AEDT ]]>